A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510945-32-00

Acronym

CT-P13 3.11

Enrollment

189

Registered

2024-12-16

Start date

2024-12-17

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Brief summary

Proportion of patients achieving clinical response according to the ACR20 criteria at Week 12.

Interventions

DRUGHYDROCORTISONE

DRUGHYDROXYCHLOROQUINE

DRUGFOLIC ACID

DRUGPARACETAMOL

DRUGRemsima 120 mg solution for injection in pre-filled pen

DRUGMETHOTREXATE

DRUGIBUPROFEN

DRUGPlacebo (To evaluate the efficacy and safety of CT-P13

DRUGand mainatain blindness during the study

DRUGPlacebo will be administered.)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of patients achieving clinical response according to the ACR20 criteria at Week 12.	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026